Hydrocortisone in Pneumonia: Evidence-Based Recommendations
Do not routinely use hydrocortisone in nonsevere community-acquired pneumonia (CAP), but strongly consider it in severe CAP requiring ICU admission, where it reduces mortality. The evidence has evolved significantly beyond the 2019 ATS/IDSA guidelines, with recent high-quality trials demonstrating clear mortality benefit in the ICU population.
Guideline Framework vs. Recent Evidence
The 2019 ATS/IDSA guidelines 1 recommend against routine corticosteroid use in both nonsevere CAP (strong recommendation) and severe CAP (conditional recommendation). However, these guidelines preceded the landmark CAPE COD trial (2023), which fundamentally changed the evidence landscape.
Critical Evidence from Recent Trials
CAPE COD Trial (2023) - The Game Changer
The CAPE COD trial 2 represents the highest quality, most recent evidence and should guide current practice:
- 800 ICU patients with severe CAP received either hydrocortisone 200 mg/day or placebo
- 28-day mortality: 6.2% vs 11.9% (absolute reduction of 5.6 percentage points, P=0.006)
- Number needed to treat: 18 to prevent one death
- Reduced need for intubation: 18.0% vs 29.5% in non-ventilated patients at baseline
- Reduced vasopressor initiation: 15.3% vs 25.0% in patients not on vasopressors at baseline
- No increase in infections or GI bleeding; only higher insulin requirements
This trial was stopped early for efficacy after the second interim analysis—a strong signal of benefit.
Contrasting Evidence: REMAP-CAP (2025)
The REMAP-CAP corticosteroid domain 3 found no mortality benefit with a fixed 7-day hydrocortisone course (50 mg q6h). However, this trial was stopped for futility, and the negative result may reflect:
- Different dosing strategy (fixed 7-day vs. clinically-guided 8-14 day course in CAPE COD)
- Shorter treatment duration
- Different patient populations and shock definitions
Meta-Analyses Support Benefit in Severe CAP
Recent meta-analyses 4, 5, 6 consistently show:
- Mortality reduction in severe CAP (OR 0.38-0.72)
- Benefit specific to hydrocortisone and longer courses (>7 days)
- Reduced mechanical ventilation rates and ICU length of stay
- No significant increase in adverse events
Practical Algorithm for Hydrocortisone Use
When to Use Hydrocortisone:
Severe CAP requiring ICU admission:
- Respiratory failure requiring mechanical ventilation OR
- Septic shock requiring vasopressors OR
- High-flow oxygen/non-invasive ventilation with clinical deterioration
Dosing regimen (based on CAPE COD):
- Hydrocortisone 200 mg/day IV (50 mg q6h or continuous infusion with 50-100 mg bolus)
- Duration: 4-7 days based on clinical improvement, then taper over total 8-14 days
- Monitor for clinical stability (shock reversal, oxygenation improvement)
When NOT to Use Hydrocortisone:
Absolute contraindications:
- Influenza pneumonia 1: Meta-analyses show increased mortality, likely due to impaired innate immunity against viral pathogens
- Nonsevere CAP not requiring ICU admission 1
Relative caution:
- Active uncontrolled infection requiring source control
- Severe immunosuppression (though recent guidance 7 suggests individualized assessment)
Exception: Septic Shock
Always use hydrocortisone in refractory septic shock (inadequate response to fluids and vasopressors), regardless of pneumonia severity 1, 8. This aligns with Surviving Sepsis Campaign guidelines.
Monitoring and Safety
Essential monitoring during treatment:
- Blood glucose q6h initially: Hyperglycemia is the most common adverse effect; treat with insulin to maintain glucose <180 mg/dL
- Electrolytes daily: Watch for hypokalemia and hypernatremia
- Clinical improvement markers: Shock reversal, oxygenation, fever resolution
After discontinuation:
- Monitor for rebound inflammation 8: Recurrence of shock or respiratory failure may occur, especially with abrupt cessation
- Consider gradual taper for courses >14 days to prevent adrenal insufficiency
- Watch for signs of adrenal insufficiency if deterioration occurs post-taper
Critical Pitfalls to Avoid
- Don't use in influenza pneumonia: This is harmful, not beneficial 1
- Don't use fixed short courses: Evidence suggests >7 days is superior to ≤7 days 5
- Don't stop abruptly after prolonged use: Taper to prevent rebound inflammation 8
- Don't withhold in severe CAP due to outdated guidelines: The 2019 recommendations predate CAPE COD 2
- Don't forget insulin: Hyperglycemia is expected and requires proactive management
Agent Selection
Hydrocortisone is the preferred agent 8, 2, 6:
- Most extensively studied in pneumonia trials
- Balanced glucocorticoid and mineralocorticoid activity
- Dose equivalents: Dexamethasone and methylprednisolone produce similar results but have less robust pneumonia-specific data
Adding fludrocortisone: Speculative benefit only; not routinely recommended 8
Bottom Line for Clinical Practice
The evidence has shifted since 2019. For severe CAP requiring ICU admission, hydrocortisone 200 mg/day for 4-7 days (with taper) reduces mortality by approximately 50% relative risk, prevents intubation, and shortens ICU stay, with manageable side effects limited primarily to hyperglycemia 2. This represents a number needed to treat of 18—a clinically meaningful benefit that outweighs risks in this critically ill population. The key is proper patient selection: use it in severe CAP, avoid it in influenza, and always use it in refractory septic shock.